Analyzing tau levels in the brain of patients with Progressive Supranuclear Palsy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate the overall tau burden in the brains of patients diagnosed with Progressive Supranuclear Palsy (PSP). Participants will receive an intervention involving F-18 AV 1451, a tracer used in molecular imaging to visualize tau protein accumulation. The study will include individuals over 35 years of age who exhibit gradual progression of PSP-related symptoms and have a reliable informant to provide additional information. The goal is to enhance understanding of tau pathology in PSP, which may inform future therapeutic strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Must be over 35 years of age and present with gradual progression of PSP-related symtoms
* Must have an informant or study partner that can provide independent information of functioning.
* Must meet criteria for possible or probable Progressive Supranuclear Palsy. To fulfill criteria for possible PSP, subjects must have a gradually progressive disorder with either vertical (upward or downward) supranuclear palsy or both slowing of vertical saccades and prominent postural instability with falls in the first year of disease onset. To fulfill criteria for probable PSP, subjects must have vertical (upward or downward gaze) supranuclear palsy and prominent postural instability with falls in the first year of disease onset.

Exclusion Criteria:

* Subjects will be excluded if they meet criteria for another neurodegenerative disease (including corticobasal syndrome, frontotemporal dementia, primary progressive aphasia, Alzheimer's disease, multiple system atrophy and Parkinson's disease) or do not have the symptoms necessary to fulfill inclusion criteria for possible PSP.
* Subjects with concurrent illnesses that could account for their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes will be excluded.
* Women that are pregnant or post-partum and breast-feeding will be excluded.
* Subjects will be excluded from the study if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome.
* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).
* Subjects will also be excluded if they do not have an informant, or do not consent to research.

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Jennifer Whitwell, PhD — Mayo Clinic
• Study coordinator: Sarah M Boland, CCRP
• Email: boland.sarah@mayo.edu
• Phone: 507-284-3863

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Wellness program for PSP and CBD: a virtual multimodal lifestyle approach

  This study tests a virtual 8-week program combining chair yoga, voice strengthening, and peer support to see if it improves emotional wellbeing and quality of life for adults with PSP or CBD and whether it eases caregiver burden.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT07844655

• Personalized magnetic brain stimulation for parkinsonian disorders

  This study will try personalized repetitive transcranial magnetic stimulation (rTMS) to see if it eases motor and non-motor symptoms in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07570212

• tDCS to improve walking and movement in PSP, corticobasal syndrome, and Parkinson's disease

  The study will try applying gentle brain stimulation (tDCS) during walking practice to see if it improves gait, speech, eye movements, and hand dexterity in people with PSP, corticobasal syndrome, or Parkinson's disease.

  Recruiting Baycrest · Toronto, Ontario · NCT07291687

• ARO-MAPT-SC in healthy adults and people with early Alzheimer's disease

  This trial will test whether ARO-MAPT-SC is safe, tolerable, and produces the expected drug levels and biomarker effects in healthy adults and people with early Alzheimer's disease.

  Recruiting at 4 sites Phase 1/2 Arrowhead Pharmaceuticals · East York, Ontario and 3 other locations · NCT07221344

• Genetic program for Progressive Supranuclear Palsy and related conditions

  This study is collecting DNA from adults with Progressive Supranuclear Palsy and similar conditions to see how genetics might help improve diagnosis and care for patients.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06647641

• Examining health services and quality of life in patients with atypical Parkinsonian syndromes

  This study looks at how people with atypical Parkinsonian syndromes, like progressive supranuclear palsy and multiple system atrophy, use health services and how their quality of life is affected by having access to specialist clinics and support services.

  Recruiting University Hospital Southampton NHS Foundation Trust · Southampton, Hampshire · NCT06645626

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.